PPA
CCCC icon

Parametric Portfolio Associates’s C4 Therapeutics CCCC Stock Holding History

Parametric Portfolio Associates’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$677K Buy
27,888
+273
+1% +$6.63K ﹤0.01% 2950
2021
Q4 		$889K Buy
27,615
+673
+2% +$26.6K ﹤0.01% 2830
2021
Q3 		$1.2M Buy
26,942
+1,297
+5% +$55.5K ﹤0.01% 2715
2021
Q2 		$970K Buy
25,645
+3,525
+16% +$126K ﹤0.01% 2785
2021
Q1 		$818K Buy
22,120
+7,916
+56% +$315K ﹤0.01% 3257
2020
Q4 		$471K Buy
+14,204
New +$412K ﹤0.01% 3412

Other funds holding CCCC

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Parametric Portfolio Associates's CCCC Position: Q1 2022 in Review

Parametric Portfolio Associates increased its C4 Therapeutics (CCCC) stake by 0.99% in Q1 2022, buying an estimated $6.63K and bringing the position to 27,888 shares worth $677K. The position accounts for ﹤0.01% of the portfolio, ranked #2950.

Parametric Portfolio Associates first reported a position in CCCC in Q4 2020 and has held it in 6 quarters since. The position peaked at $1.2M in Q3 2021. 125 funds tracked by Wall St. Rank hold CCCC as of Q1 2022.

  • Parametric Portfolio Associates held 27,888 shares of C4 Therapeutics worth $677K as of Q1 2022.
  • Parametric Portfolio Associates bought 273 C4 Therapeutics shares in Q1 2022, an estimated $6.63K.
  • C4 Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2950 holding.
  • Parametric Portfolio Associates first reported a position in C4 Therapeutics in Q4 2020 and has held it in 6 quarters since.
  • Parametric Portfolio Associates's C4 Therapeutics position peaked at $1.2M in Q3 2021.
  • 125 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.